Insider · CIK 0001553335
Jakob Dupont
Files at BOLT (Bolt Biotherapeutics, Inc.), PYXS (Pyxis Oncology, Inc.). First filing -, latest -.
Jakob Dupont files SEC Form 4 as director at BOLT (Bolt Biotherapeutics, Inc.), and also at PYXS (Pyxis Oncology, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jakob Dupont has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 30, 2026 | PYXS Pyxis Oncology, Inc. | 35,000 0.06% of outstanding | $107k | Jun 30, 2026 | none |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | BOLT Bolt Biotherapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jun 11, 2026 |
| Mar 24, 2026 | PYXS Pyxis Oncology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +45,867 | $0.00 | $0 | 45,867 | Mar 25, 2026 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +2,500 | - | - | 2,500 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -2,500 | - | - | 0 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +849 | - | - | 849 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -849 | - | - | 0 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +1,000 | - | - | 1,000 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -1,000 | - | - | 0 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +1,100 | - | - | 1,100 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -1,100 | - | - | 0 | Dec 16, 2025 |
| May 27, 2025 | BOLT Bolt Biotherapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +1,100 | $0.00 | $0 | 1,100 | Jul 2, 2025 |
| May 1, 2025 | BOLT Bolt Biotherapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | May 5, 2025 |
| Mar 31, 2025 | PYXS Pyxis Oncology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +36,979 | $0.98 | $36k | 36,979 | Apr 2, 2025 |
Questions about Jakob Dupont
Answered from the filings on this page, as of the latest one.
Is Jakob Dupont buying or selling?
Jakob Dupont has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jakob Dupont's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jakob Dupont has 0.
Where does Jakob Dupont file Form 4?
Jakob Dupont has filed Form 4 at BOLT (Bolt Biotherapeutics, Inc.); PYXS (Pyxis Oncology, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.